GILEAD SCIENCES, INC. vs VERTEX PHARMACEUTICALS INC / MA, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GILD and VRTX diverge most: on debt / equity, GILD reads 1.00 and VRTX reads 0.00; on revenue growth, GILD reads +3.5% and VRTX reads +10.1%. The rest of the comparable metrics sit closer together. What VRTX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | GILD | VRTX |
|---|---|---|
| Price | $130.19 | $477.02 |
| Market cap | $163.3B | $122.3B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +20.7% |
| P/E | 17.7 | 28.3 |
| P/B | 6.94 | 6.31 |
| P/S | 5.49 | 10.01 |
| EV/EBITDA | 17.4 | 23.8 |
| Revenue growth | +3.5% | +10.1% |
| Operating margin | 37.2% | 38.1% |
| Net margin | 31.0% | 35.5% |
| Return on equity | 39.2% | 22.4% |
| Return on assets | 16.4% | 16.4% |
| Return on invested capital | 17.3% | 19.9% |
| FCF yield | 6.3% | 3.0% |
| Dividend yield | 2.4% | — |
| Debt / equity | 1.00 | 0.00 |
| Current ratio | 1.97 | 3.02 |
| Altman Z (solvency) | 7.23 | 7.73 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.